Whether politicians choose to accept it or not, the countries of the world are engaged in a race to vaccinate their populations against the novel coronavirus - and winners are already beginning to emerge.
Responding to delays in the manufacture and supply of vaccines from Pfizer (NYSE: PFE) and AstraZeneca (LSE: AZN), the European Union’s recent tough talk on blocking exports reflects rising concern on the continent that the trading bloc has been slow off the starting blocks.
Warning that “Europe invested billions to help develop the world’s first COVID-19 vaccines,” EU Commission President Ursula von der Leyen said “companies must deliver. They must honor their obligations.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze